In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to ...

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences ...

They want to make sure we've got more control over that supply chain, so DARPA and the federal government are really ...

Clinical Affairs plays a central role in ensuring that CGM promotional claims are accurate, evidence-based, and compliant. By ...

Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...

Pharmaceutical Executive: How are new vaccine technologies impacting the vaccine space? Sylvia Taylor: Vaccine technologies ...

Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico ...

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim ...

AbbVie entered into an agreement to acquire Apogee Therapeutics at a price of $135.11 for each outstanding. The deal is expected to be worth about $10.9 billion and will add Apogee’s entire pipeline ...

Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...

As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...